Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Illumina Forms Diagnostics Pact With Big Pharma

by Ann M. Thayer
September 1, 2014 | A version of this story appeared in Volume 92, Issue 35

Illumina has set up a partnership with three major pharmaceutical firms to develop a next-generation sequencing-based oncology test system for use in the partners’ clinical trials. The initial pharma partners are AstraZeneca, Sanofi, and Janssen Biotech. The system will simultaneously sequence multiple cancer-related genes to match patients with targeted therapies. According to Illumina, 125 known genes that drive cancer growth have been discovered, and an estimated 800 oncology drugs, many of which target specific gene mutations, are in development. The overall goal is to gain regulatory approval and commercialize new therapies in combination with gene-panel-based companion diagnostics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.